Tesamorelin

Category: peptide

Aliases: Egrifta, TH9507

Pharmacological Mechanism

Full-length GHRH (1-44) conjugated with trans-3-hexenoic acid at the N-terminus — blocks DPP-IV degradation and extends plasma t½. FDA-approved for reducing visceral adipose tissue (VAT) in HIV-associated lipodystrophy. Durable GH-pulse restoration with preserved pituitary negative feedback.

Half-Life (t½)

SC: 0.13h

Dosing Guidelines

• SC: Typical 2mg (Range: 2 - 2 mg)

Target Organ Systems

• endocrine